Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis

  • Authors:
    • Xuejiao Sun
    • Shishi Niu
    • Zhen Zhang
    • Anyan Wang
    • Chengyuan Yang
    • Zichan Guo
    • Yuepeng Hao
    • Xiaozhong Li
    • Xiaoxia Wang
  • View Affiliations

  • Published online on: February 27, 2019     https://doi.org/10.3892/mmr.2019.9996
  • Pages: 3841-3847
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Angiogenesis serves a key role in tumor growth and metastasis. VX‑680, a potent inhibitor targeting the Aurora kinase family, is widely used in the inhibition of tumor progression. However, the effect of VX‑680 on angiogenesis remains unknown. The present study identified that VX‑680 inhibited human umbilical vein endothelial cell (HUVEC) proliferation and promoted HUVEC apoptosis by inducing the cleavage of PARP and caspase‑3. VX‑680 also markedly decreased the migration and tube formation of HUVECs in a dose‑dependent manner. In addition, VX‑680 significantly suppressed the formation of blood vessels in a dose‑dependent manner confirmed by a chicken embryo chorioallantoic membrane assay in vivo. Furthermore, VX‑680 inhibited the expression levels of vascular endothelial growth factor and phosphorylated RAC‑α serine/threonine‑protein kinase in HUVECs. These results suggested that VX‑680 suppressed angiogenesis and may be a potential novel anti‑angiogenic agent.

References

1 

Kubota Y: Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Abdelrahim M, Konduri S, Basha R, Philip PA and Baker CH: Angiogenesis: An update and potential drug approaches. Int J Oncol. 36:5–18. 2010.PubMed/NCBI

3 

Su M, Huang J, Li J, Qin X, Tang X, Jin F, Chen S, Jiang C, Zou Z, Peng K, et al: ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling. Oncotarget. 7:19018–19030. 2016.PubMed/NCBI

4 

Saraswati S, Kanaujia PK, Kumar S, Kumar R and Alhaider AA: Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis. Mol Cancer. 12:822013. View Article : Google Scholar : PubMed/NCBI

5 

Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, et al: Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 14:6106–6115. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Doggrell SA: Dawn of Aurora kinase inhibitors as anticancer drugs. Expert Opin Investig Drugs. 13:1199–1201. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Cheetham GM, Charlton PA, Golec JM and Pollard JR: Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 251:323–329. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, et al: Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 14:5437–5446. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Jin X, Mo Q, Zhang Y, Gao Y, Wu Y, Li J, Hao X, Ma D, Gao Q and Chen P: The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer. Cancer Biol Ther. 17:566–576. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, Qian CN, Resau JH, Kim H and The BT: VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res. 2:296–308. 2010.PubMed/NCBI

11 

Xu DR, Huang S, Long ZJ, Chen JJ, Zou ZZ, Li J, Lin DJ and Liu Q: Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells. J Transl Med. 9:742011. View Article : Google Scholar : PubMed/NCBI

12 

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, et al: MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 27:113–117. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Pezzani R, Rubin B, Bertazza L, Redaelli M, Barollo S, Monticelli H, Baldini E, Mian C, Mucignat C, Scaroni C, et al: The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. Invest New Drugs. 34:531–540. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Sun JM, Yang LN, Xu H Chang B, Wang HY and Yang G: Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res. 5:1133–1145. 2015.PubMed/NCBI

15 

Yao R, Zheng J, Zheng W, Gong Y, Liu W and Xing R: VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett. 7:121–124. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y and D'Onofrio A: Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today. 16:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 62:179–213. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Cui HJ, Yang AL, Zhou HJ, Wang C, Luo JK, Lin Y, Zong YX and Tang T: Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage. BMC Complement Altern Med. 15:912015. View Article : Google Scholar : PubMed/NCBI

19 

Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G and Shen L: Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 6:44563–44578. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Sharma S, Guru SK, Manda S, Kumar A Mintoo MJ, Prasad VD, Sharma PR, Mondhe DM, Bharate SB and Bhushan S: A marine sponge alkaloid derivative 4-chloro fascaplysin inhibits tumor growth and VEGF mediated angiogenesis by disrupting PI3K/Akt/mTOR signaling cascade. Chem Biol Interact. 275:47–60. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, et al: Aurora-A Kinase: A potent oncogene and target for cancer therapy. Med Res Rev. 36:1036–1079. 2016. View Article : Google Scholar : PubMed/NCBI

22 

D'Assoro AB, Haddad T and Galanis E: Aurora-A kinase as a promising therapeutic target in cancer. Front Oncol. 5:2952016.PubMed/NCBI

23 

Portella G, Passaro C and Chieffi P: Aurora B: A new prognostic marker and therapeutic target in cancer. Curr Med Chem. 18:482–96. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, et al: A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 4:e2382014. View Article : Google Scholar : PubMed/NCBI

25 

Ponce ML: Tube formation: An in vitro matrigel angiogenesis assay. Methods Mol Biol. 467:183–188. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA. 99:11399–11404. 2002. View Article : Google Scholar : PubMed/NCBI

27 

Saraswati S, Kumar S and Alhaider AA: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer. 12:1472013. View Article : Google Scholar : PubMed/NCBI

28 

Du J, Wang R, Yin L, Fu Y, Cai Y, Zhang Z and Liang A: BmK CT enhances the sensitivity of temozolomide-induced apoptosis of malignant glioma U251 cells in vitro through blocking the AKT signaling pathway. Oncol Lett. 15:1537–1544. 2018.PubMed/NCBI

Related Articles

Journal Cover

May 2019
Volume 19 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sun, X., Niu, S., Zhang, Z., Wang, A., Yang, C., Guo, Z. ... Wang, X. (2019). Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis . Molecular Medicine Reports, 19, 3841-3847. https://doi.org/10.3892/mmr.2019.9996
MLA
Sun, X., Niu, S., Zhang, Z., Wang, A., Yang, C., Guo, Z., Hao, Y., Li, X., Wang, X."Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis ". Molecular Medicine Reports 19.5 (2019): 3841-3847.
Chicago
Sun, X., Niu, S., Zhang, Z., Wang, A., Yang, C., Guo, Z., Hao, Y., Li, X., Wang, X."Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis ". Molecular Medicine Reports 19, no. 5 (2019): 3841-3847. https://doi.org/10.3892/mmr.2019.9996